I fase I doseringsundersøgelser i patienter med mild til moderat tumorindiceret hypercalcæmi (TIH), var den afprøvede effektive dosis cirka 1, 2– 2, 5 mg.
In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2– 2.5 mg.